

Defining erythema dyschromicum perstans, ashy dermatosis, lichen planus pigmentosus and idiopathic eruptive macular pigmentation: A global consensus needed

A Anderson¹, B Wood², S P Kumarasinghe³

Sri Lanka Journal of Dermatology, 2012-2014, 16, 20-22

The conditions erythema dyschromicum perstans (EDP), ashy dermatosis, lichen planus pigmentosus (LPP) and idiopathic eruptive macular pigmentation (IEMP) are commonly confused and poorly defined. It is debated whether they are indeed discrete entities, or variations in presentation and description of the same disease process¹. Part of the confusion stems from the poor understanding of the pathogenesis of these conditions.

Ashy Dermatitis was first described as 'Dermatosis Cenicienta'² by Ramirez, who reported 139 patients with macular grey hyperpigmentation, sometimes with an erythematous border. Histopathologically, basal vacuolar change was seen, in addition to dermal melanosis and a perivascular inflammatory infiltrate. The name erythema dyschromicum perstans was used by Convit, Kerdel-Vegas and Rodriguez-Garcilazo in 1961 to describe what many consider to be the same condition^{3,4}. The subtle erythema described in typical cases of EDP is not usually seen in darker skinned patients. Most authors agree that erythema dyschromicum perstans and ashy dermatosis are the same condition^{9,10,11,12}, however this is not universally accepted^{13,15}.

IEMP was originally described by Degos⁵. The main differences between EDP/ashy dermatosis and IEMP were proposed to be an absence of preceding erythema and an absence of vacuolar interface change^{5,6}. It has also been argued that IEMP can be differentiated from EDP due to a brownish, rather than grey pigmentation¹⁴. Histopathologically IEMP is described as showing only basal keratinocytic hyperpigmentation, in contrast to the vacuolar change and pigmentary incontinence seen in EDP/ashy dermatosis. Some authors however disagree with the distinction of these conditions based on clinical colour or histopathology⁷, suggesting that the presence of basal vacuolar change depends on the time of biopsy in relation to the activity of the condition. The diagnosis of IEMP has been further complicated by the description IEMP with papillomatosis, where some lesions show velvety thickening¹⁷.

In a strict sense this description is a contradiction to the 'macular' description of IEMP.

Based on the presence of interface change on histopathology, and a similar clinical appearance to 'burnt out' lichen planus, it has further been suggested that EDP/ashy dermatosis may be variants of lichen planus and be the same condition as lichen planus pigmentosus^{3,8}, though some argue against this suggested grouping^{10,16}. Most reported cases of EDP/ashy dermatosis have no other evidence of typical lichen planus. EDP and AD most commonly present in children, in whom lichen planus is uncommon. EDP does not show Max-Joseph spaces on histopathology⁸, though this could be explained by the temporal variation hypothesis.

The disagreement between authors in regards to the ways in which to differentiate or unify EDP, ashy dermatosis, lichen planus pigmentosus and IEMP suggest that the clinical and histopathological presentations of these conditions are somewhat blurred¹⁶. In addition, there is a poor understanding of the pathogenesis of this group of conditions and treatment for all is generally ineffective⁸.

We suggest that until further evidence is accrued, the terms EDP and ashy dermatosis be considered to describe a morphological spectrum of acquired macular pigmentation associated with evidence of a current or resolved vacuolar interface dermatitis with post-inflammatory pigment alteration. Patients with clinical or histopathological features of lichen planus with post inflammatory pigment alteration can be described as having lichen planus pigmentosus. Frequent resolution and the finding of basal hyperpigmentation without significant pigmentary incontinence suggest that IEMP may have a different aetiology. From a pathological standpoint, familiarity with racial and individual variations in pigmentation and close correlation with the clinical findings and biopsy site are critical to microscopic assessment of these findings. It is accepted that these terms may describe slight clinical and histopathological variations in the same disease process, or several disease processes which present in a similar manner (acquired macular pigmentation).

¹Dermatology Registrar, ²Clinical Associate, Department of Dermatology, Royal Perth Hospital, Perth, WA 6000, Australia, ³Consultant Pathologist, PathWest Laboratory Medicine and Clinical Senior Lecturer, School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands WA 6009, Australia.

More critical from a clinical standpoint is that these idiopathic and treatment resistant conditions be separated from other causes of hyperpigmentation with identifiable specific and potentially treatable causes and those with important systemic implications. To this end, the important clinical and histological differential diagnoses are outlined in

Tables 1 and 2 respectively. Figure 1 shows a proposed simplified clinical diagnostic flow chart of the approach to these conditions based on published data and authors' synthesis. This proposed algorithm helps to categorize acquired macular hyperpigmentation due to unknown causes.




Figure 1. Proposed algorithm for acquired macular hyperpigmentation based on current published data and authors' synthesis.

Table 1. Clinical differential diagnoses of EDP, AD, LPP, IEMP

<p><i>Post inflammatory</i></p> <p>Fixed drug eruption</p> <p>Pigmented contact dermatitis/ Riehl's melanosis</p> <p>'Burnt out' graft versus host disease</p> <p>Post inflammatory hyperpigmentation, e.g. viral exanthem, pityriasis rosea</p> <p><i>Systemic disorders</i></p> <p>Addison's disease</p> <p>Mastocytosis</p> <p>Pigmentation secondary to dermatomyositis</p> <p><i>Non-melanin pigmentation</i></p> <p>Argyria</p> <p>Drug induced pigmentation (e.g. amiodarone, minocycline)</p> <p>Ochronosis</p>	<p><i>Others (miscellaneous)</i></p> <p>Mycosis fungoides</p> <p>Melasma</p> <p>Hori's nevus</p> <p>Macular amyloidosis</p> <p>Confluent and reticulate papillomatosis</p> <p>Melanoderma secondary to advanced melanoma</p> <p>Aberrant persistent Mongolian blue spots</p> <p>Phacomatosis pigmentovascularis</p> <p>Pigmented seborrhoeic keratosis</p> <p>Pityriasis versicolor</p> <p>Ephelides</p> <p>Solar lentigo</p> <p>Post-radiotherapy hyperpigmentation</p> <p>Erythema ab igne</p> <p>Phytophotodermatitis</p> <p>Dowling-Degos disease</p>
---	---

Table 2. Histopathological mimics of EDP/AD/LPP

Resolved benign lichenoid keratosis
Fixed drug eruption
Riehl's melanosis/ pigmented contact dermatitis
Resolved drug eruption (post inflammatory hyperpigmentation)
Drug induced hyperpigmentation (slowly progressive/ ongoing)
Resolved viral exanthem
Dermatomyositis
"Burnt out" graft versus host disease
Ephelides
Lentigens
'Normal skin' with occasional dermal melanophages (in dark skinned races)

References

1. Torrelo A, Zaballos P, Colmenero I, *et al.* Erythema dyschromicum perstans in children: a report of 14 cases. *J EADV* 2005; **19**: 422-6.
2. Raimerez CO. Los Cenicientos (1957) Problema Clinico. In: Report of the first Central American Congress of Dermatology, San Salvador, December 5-8, 1957.
3. Convit J, Kerderl- Vegas F, Rodriguez G. Erythema dyschromicum perstans. A hitherto undescribed skin disease. *J Invest Dermatol* 1961; **36**: 457-62.
4. Letter: Erythema dyschromicum perstans revisited. Mauricio Goihman- Yar. *Dermatology Online Journal* **17** (1): 14.
5. Degos R, Civatte J, Belaich S. Idiopathic eruptive macular pigmentation. *Ann Dermatol Venereol* 1978; **105**(2): 177-82.
6. Volz A, Metze D, Bohm M, *et al.* Idiopathic eruptive macular pigmentation in a 7 year old girl: case report and discussion of differences from erythema dyschromicum perstans. *BJD* 2007; **157**: 799-846.
7. Zaynoun S, Rubeiz N, Kibbi AG. Ashy dermatoses – a critical review of the literature and a proposed simplified clinical classification. *Int Journal of Dermatology* 2008; **47**: 542-4.
8. Bhutani LK. Ashy dermatosis or lichen planus pigmentosus: what is in a name? *Arch Dermatol* 1986; **122**(2): 133.
9. Schwartz, R. Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis. *Int J Dermatol* 2004; **43**: 230-2.
10. Vasquez-Ochoa, Isaza-Guzman, Orozco-Mora, *et al.* Immunopathologic study of erythema dyschromicum perstans (ashy dermatosis). *Int Journal of Dermatology* 2007; **45**: 937-41.
11. Stevenson JR, Miura M. Erythema dyschromicum perstans (Ashy dermatosis). *Arch Dermatol* 1966; **94**: 196-9.
12. Ramirez O, Lopez Lino DG. Current status of ashy dermatosis. Synonym-erythema dyschromicum perstans. *Med Cutan Ibero Lat Am* 1984; **12**: 11-18.
13. Degos R, Civatte J, Belaich S. Idiopathic eruptive macular pigmentation. *Ann Dermatol Venereol* 1978; **105**(2): 177-82.
14. Jang KA, Choi JH, Sung KS, *et al.* Idiopathic eruptive macular pigmentation: report of 10 cases. *J Am Acad Dermatol* 2001; **44**: 351-3.
15. Combemale P, Faisant M, Guennoc B, *et al.* Erythema dyschromicum perstans: a report of a new case and a critical review of the literature. *J Dermatol* 1998; **25**: 747-5
16. Kumarasinghe SPW, Kumarasinghe MP. Lichen planus pigmentosus, ashy dermatosis, erythema dyschromicum perstans or acquired spontaneous macular hyperpigmentation? *Sri Lanka Journal of Dermatology* 1998; **3**: 16-19.
17. Joshi R. Idiopathic eruptive macular pigmentation with papillomatosis: a report of nine cases. *Indian J Dermatol Venereol Leprol* 2007; **73**: 402-5.